Literature DB >> 10861578

Proliferative index in phaeochromocytomas: does it predict the occurrence of metastases?

E van der Harst1, H A Bruining, H Jaap Bonjer, F van der Ham, W N Dinjens, S W Lamberts, W W de Herder, J W Koper, T Stijnen, C Proye, M Lecomte-Houcke, F T Bosman, R R de Krijger.   

Abstract

Evaluation of the malignant potential of phaeochromocytomas in the absence of metastases presents a formidable challenge to both clinicians and pathologists. Until now, no widely accepted clinical, histological, immunohistochemical or molecular method has become available to discriminate malignant from benign phaeochromocytomas. In other endocrine tumours, estimation of proliferative activity by MIB-1 immunostaining has emerged as a promising approach for the determination of metastatic potential. In this study, the utility of MIB-1 immunostaining as a predictive marker for the occurrence of metastases in phaeochromocytomas was evaluated. In addition, the density of S100-positive sustentacular cells was studied, since their depletion has been identified as a negative predictive marker in smaller series. Furthermore, several clinicopathological parameters were evaluated. One hundred and ten patients operated on for a total of 99 benign and 37 malignant phaeochromocytomas were studied. All malignant tumours had documented metastases. The histopathological diagnosis of primary tumours and metastases was reviewed and graded for angioinvasion, capsular extension, and intra-tumoural necrosis. The proliferative index (percentage of MIB-1-positive cells) and the density of S100-positive cells were assessed. In addition, age at resection, associated familial tumour syndromes, tumour size, and tumour location were recorded. Univariate analysis revealed statistically significant correlations between malignancy and proliferative index (p<0.0005) and depletion of S100-positive sustentacular cells (p<0.0005). Fifty per cent of the malignant, but none of the benign phaeochromocytomas had a proliferative index greater than 2.5%. Higher age at resection (p=0. 03), sporadic occurrence (p<0.0005), extra-adrenal location (p<0. 0005), tumour size (p<0.0005), and necrosis (p=0.03) were also significantly associated with malignancy. Logistic regression showed that proliferative index (p=0.0072), size (p=0.0022), and extra-adrenal location (p=0.0012) of the primary tumour were independently predictive for malignancy. In conclusion, this study indicates that assessing the proliferative activity of phaeochromocytomas by MIB-1 immunohistochemistry can predict the occurrence of metastases. The predictive value of S100 immunostaining, tumour size, and extra-adrenal location of the tumour was also confirmed. Copyright 2000 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10861578     DOI: 10.1002/(SICI)1096-9896(200006)191:2<175::AID-PATH615>3.0.CO;2-Z

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  21 in total

Review 1.  Endocrine pathology in translational medicine: an overview of current and future prospects.

Authors:  Robert Yoshiyuki Osamura; Nobue Kumaki; Hiroshi Kajiwara; Noboru Egashira; Syunsuke Miyai; Susumu Takekoshi; Masanori Yasuda; Shinobu Umemura
Journal:  Endocr Pathol       Date:  2003       Impact factor: 3.943

2.  Malignant pheochromocytoma: new malignancy criteria.

Authors:  Pierre de Wailly; Luigi Oragano; Francois Radé; Anthony Beaulieu; Vincent Arnault; Pierre Levillain; Jean Louis Kraimps
Journal:  Langenbecks Arch Surg       Date:  2011-11-09       Impact factor: 3.445

3.  Malignant paraganglioma of the urinary bladder: Immunohistochemical study of prognostic indicators.

Authors:  Kalman Kovacs; David Bell; Geoffrey W Gardiner; R John Honey; Jeannette Goguen; Fabio Rotondo
Journal:  Endocr Pathol       Date:  2005       Impact factor: 3.943

Review 4.  Pheochromocytomas and paragangliomas: assessment of malignant potential.

Authors:  Tim I M Korevaar; Ashley B Grossman
Journal:  Endocrine       Date:  2011-10-25       Impact factor: 3.633

Review 5.  Diagnostic tests and biomarkers for pheochromocytoma and extra-adrenal paraganglioma: from routine laboratory methods to disease stratification.

Authors:  Graeme Eisenhofer; Arthur S Tischler; Ronald R de Krijger
Journal:  Endocr Pathol       Date:  2012-03       Impact factor: 3.943

Review 6.  Malignant pheochromocytomas and paragangliomas: a diagnostic challenge.

Authors:  Oliver Gimm; Catherine DeMicco; Aurel Perren; Francesco Giammarile; Martin K Walz; Laurent Brunaud
Journal:  Langenbecks Arch Surg       Date:  2011-11-29       Impact factor: 3.445

7.  18F-FLT PET/CT in the Evaluation of Pheochromocytomas and Paragangliomas: A Pilot Study.

Authors:  Elise M Blanchet; David Taieb; Corina Millo; Victoria Martucci; Clara C Chen; Maria Merino; Peter Herscovitch; Karel Pacak
Journal:  J Nucl Med       Date:  2015-09-10       Impact factor: 10.057

8.  Prediction of malignant behavior of pheochromocytomas and paragangliomas using immunohistochemical techniques.

Authors:  Nobue Kumaki; Hiroshi Kajiwara; Kaori Kameyama; Ronald A DeLellis; Sylvia L Asa; R Yoshiyuki Osamura; Hiroshi Takami
Journal:  Endocr Pathol       Date:  2002       Impact factor: 3.943

9.  Carcinoma-like nonfunctional pheochromocytoma in the right adrenal gland: A case report.

Authors:  Shingo Moriyama; Hideki Takeshita; Saori Araki; Takuo Tokairin; Makoto Kagawa; Koji Chiba; Akiko Adachi; Akira Noro
Journal:  Oncol Lett       Date:  2016-06-23       Impact factor: 2.967

Review 10.  Molecular genetic alterations in adrenal and extra-adrenal pheochromocytomas and paragangliomas.

Authors:  Hilde Dannenberg; Paul Komminoth; Winand N M Dinjens; Ernst Jan M Speel; Ronald R de Krijger
Journal:  Endocr Pathol       Date:  2003       Impact factor: 3.943

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.